Luteolytic effect of LH: inhibition of 3β-hydroxysteroid dehydrogenase and stimulation of 20α-hydroxysteroid dehydrogenase luteal activities in late pregnant rats

1996 ◽  
Vol 150 (3) ◽  
pp. 423-429 ◽  
Author(s):  
C O Stocco ◽  
R P Deis
Keyword(s):  
Hydroxysteroid Dehydrogenase ◽  
Good Evidence ◽  
Progressive Decrease ◽  
Control Groups ◽  
Serum Progesterone ◽  
Pregnant Rats ◽  
Pregnant Rat ◽  
Luteal Function ◽  
Treatment Administration ◽  
Stimulation Of

Abstract The mechanisms associated with the onset of luteolysis in the pregnant rat are not well known. The effect of a specific rat LH antiserum (AS-rLH) and of ovine LH (oLH) on luteal steroidogenesis on day 19 of pregnancy was examined. Rat LH antiserum administered intrabursally at 1000–1100 h on day 19 of pregnancy prevented the physiological decrease in 3β-hydroxysteroid dehydrogenase (3β-HSD) activity, the increase in 20α-hydroxysteroid dehydrogenase (20α-HSD) activity and the fall in serum progesterone (P4) level observed at 1800 h on day 21 of pregnancy. To see if oLH has a direct effect on luteal steroidogenesis, the gonadotrophin was injected into the periovarian bursa. The intrabursa treatment with 1 μg oLH on day 19 of pregnancy at 0800–0900 h did not modify corpus luteal function 36 h after treatment, but treatment with 4 μg oLH per ovary induced a significant progressive decrease in luteal 3β-HSD activity starting 12 h after treatment, while a significant increase in 20α-HSD activity, concomitant with a decrease in serum P4 level, occurred 48 h after treatment. Luteal P4 content decreased with respect to control groups 36 and 48 h after intrabursal treatment with 4 μg oLH. The intrabursal administration of 8 μg oLH induced an increase in 20α-HSD activity and a decrease in 3β-HSD activity 36 h after treatment. Administration of 4 μg oLH per ovary on day 8 of pregnancy induced a significant increase in serum P4 levels without modifying 3β-HSD activity. In rats treated with oLH on day 19 of pregnancy the decrease in 3β-HSD activity occurred 36 h before the significant increase in 20α-HSD activity and serum P4 level. In conclusion, the luteal enzymatic activity changes and the significant decrease in the intraluteal P4 concentration induced by the intrabursal administration of oLH and the clear effect of AS-rLH preventing the physiological luteal changes preceding parturition provide good evidence of an intraovarian action of LH during the normal progression of luteolysis in late pregnant rats. Journal of Endocrinology (1996) 150, 423–429

scholarly journals Participation of intraluteal progesterone and prostaglandin F2 alpha in LH-induced luteolysis in pregnant rat

1998 ◽  
Vol 156 (2) ◽  
pp. 253-259 ◽  
Author(s):  
CO Stocco ◽  
RP Deis
Keyword(s):  
Corpus Luteum ◽  
Dehydrogenase Activity ◽  
Subcutaneous Administration ◽  
Hydroxysteroid Dehydrogenase ◽  
Good Evidence ◽  
Pregnant Rats ◽  
Pregnant Rat ◽  
Prostaglandin F2 Alpha

We examined the participation of the intraluteal levels of progesterone (P4) and prostaglandin F2 alpha (PGF2 alpha) in the induction of luteolysis by LH and its relationship with the induction of the 20 alpha-hydroxysteroid dehydrogenase activity (20 alpha-HSD). Subcutaneous administration of four doses of 10 microgram ovine LH (oLH) at 0800, 0900, 1000 and 1100 h on day 19 of pregnancy induced a decrease in the activity of the enzyme 3 beta-HSD 24 and 48 h after treatment and an increase in luteal 20 alpha-HSD activity 48 h after oLH treatment when compared with control rats. Intraluteal and serum P4 levels were lower than control values 24 and 48 h after oLH treatment, with a significant increase in luteal PGF2 alpha content and a decrease in corpus luteum (CL) weight 48 h after oLH treatment. Intrabursal ovarian (i.b.) treatment with an inhibitor of PG's biosynthesis (diclofenac) (70 microgram/ovary) or P4 (3 microgram/ovary) on day 20 of pregnancy, prevented the increase in 20 alpha-HSD activity observed 48 h after oLH treatment, without any effect on 3 beta-HSD activity. The i.b. administration of P4 prevented the increase in intraluteal PGF2 alpha content induced by oLH treatment and the increases in 20 alpha-HSD activity and intraluteal PGF2 alpha content observed in control animals on day 21 of pregnancy. The inhibition of PG biosynthesis also prevents the decrease in intraluteal and serum P4 level induced by oLH. These results provide good evidence of the important participation of intraluteal P4 and PGF2 alpha on the oLH-induced luteolysis in pregnant rats. We also found the P4 produced by the CL is involved, in part, in the regulation of luteal PG synthesis. Thus, the early decline in 3 beta-HSD activity and the consequent fall in intraluteal P4 content, may trigger the synthesis of PGs and thereafter the increase in luteal 20 alpha-HSD activity to establish luteolysis.

Potentiation by prolactin of the luteotrophic effect of oestradiol in the pregnant rat

1982 ◽  
Vol 101 (2) ◽  
pp. 287-292 ◽  
Author(s):  
Richard G. Rodway ◽  
David R. Garris
Keyword(s):  
Sampling Period ◽  
Daily Treatment ◽  
Serum Prolactin ◽  
Renal Capsule ◽  
Serum Progesterone ◽  
Pregnant Rats ◽  
Pregnant Rat ◽  
Luteal Function ◽  
Progesterone Secretion

Abstract. The luteotrophic effects of elevated prolactin levels with or without concomitant oestradiol treatment were investigated in the pregnant rat after hysterectomy or hysterectomy plus hypophysectomy. On day 2 of pregnancy, rats were given a single pituitary transplant beneath the renal capsule and were subsequently hysterectomised on day 12. This treatment delayed the next ovulation (as judged by vaginal di-oestrus length) compared to sham-transplanted controls, but did not prevent the fall in serum progesterone concentrations (i.e. luteolysis) resulting from hysterectomy. The administration of 1 or 2 pituitary homo-transplants on day 12 at the time of hysterectomy again prolonged the di-oestrus length but did not prevent subsequent luteolysis. However, daily treatment with 100 μg of oestradiol given to rats which received 2 pituitary transplants on day 2 and which were then hysterectomised on day 12, did result in a maintenance of serum progesterone levels compared to those of oil-treated controls. In a separate study, pregnant rats were hysterectomised and hypophysectomised on day 12. Administration of either 1 or 2 pituitary transplants failed to maintain luteal function. However, concomitant daily treatment with 100 μg of oestradiol from day 12 onward prevented luteolysis and re-instated the day 12–16 rise in serum progesterone common to the intact pregnant rat. Progesterone levels then declined slowly until the end of the sampling period (day 23). Serum prolactin concentrations rose steadily for the first 10 days after insertion of pituitary transplants on day 12 of pregnancy. These data indicate that prolactin and oestradiol can act synergistically to stimulate progesterone secretion from the rat corpus luteum but only in the absence of the in situ pituitary; the effect is not seen unless hypophysectomy has been performed.

A modulatory role of endogenous opioids on prolactin secretion at the end of pregnancy in the rat

1994 ◽  
Vol 140 (1) ◽  
pp. 97-102 ◽  
Author(s):  
M Soaje ◽  
R P Deis
Keyword(s):  
Time Course ◽  
Prolactin Secretion ◽  
Endogenous Opioids ◽  
Opioid Antagonist ◽  
Serum Prolactin ◽  
Serum Progesterone ◽  
Pregnant Rats ◽  
Pregnant Rat ◽  
Ru 486 ◽  
Prolactin Suppression

Abstract It is well known that the fall in serum progesterone concentrations during late pregnancy induces prolactin secretion in rats. On day 19 of pregnancy, administration of 10 mg of the antiprogesterone RU-486/kg induced a small but significant increase in serum prolactin. A lower dose (2 mg/kg) was not effective. Administration of naloxone (2 mg/kg) to pregnant rats on day 19 of pregnancy did not modify circulating prolactin but, after RU-486 treatment, a notable increase in serum prolactin was obtained 30 min after naloxone was given. The lack of effect of naloxone-methobromide in pregnant rats pretreated with RU-486 may indicate that the opioid-induced prolactin suppression acts centrally, most probably at the hypothalamic level. During day 21 of pregnancy, the time-course of prolactin secretion, measured at 0900, 1400, 1900 and 2200 h, was inversely correlated with circulating progesterone levels. At 0900 h, serum prolactin was very low with high serum progesterone concentrations but a significant increase in serum prolactin occurred at 2200 h; this was coincident with a significant decrease in the steroid. The stimulatory effect of naloxone on prolactin secretion was clearly dependent on the circulating progesterone level. Thus, at 1900 h of day 21, naloxone induced a significant increase in serum prolactin but, at 2200 h, the opioid antagonist dramatically enhanced the circulating level of prolactin. The serum prolactin increase induced by naloxone at 1900 h was prevented by the s.c. administration of 5 mg progesterone given 7 h earlier. Similarly, the large increase in serum prolactin levels at 1800 h on day 19 of pregnancy, after administration of RU-486 plus naloxone, was completely abolished by treatment with CB154. The lack of effect of RU-486 and naloxone on serum prolactin levels in virgin rats on the day of pro-oestrus demonstrates that the effect of naloxone on prolactin in pregnant rat is peculiar to the end of pregnancy. In conclusion, the attenuation of the central inhibitory action of progesterone facilitates the release of prolactin which is dramatically enhanced by naloxone treatment. These results provide an important new insight into the existence of a neuromodulatory regulation of prolactin secretion by the opioid system showing a paradoxical opioid-induced prolactin suppression at the end of pregnancy. Journal of Endocrinology (1994) 140, 97–102

scholarly journals Hypothyroidism prolongs corpus luteum function in the pregnant rat

Reproduction ◽  
2007 ◽  
Vol 133 (1) ◽  
pp. 197-205 ◽  
Author(s):  
María Belén Hapon ◽  
Alicia B Motta ◽  
Marcelo Ezquer ◽  
Melisa Bonafede ◽  
Graciela A Jahn
Keyword(s):  
Western Blot ◽  
Corpus Luteum ◽  
Blot Analysis ◽  
Inos Mrna ◽  
Rt Pcr ◽  
Pregnant Rat ◽  
Luteal Regression ◽  
Luteal Function ◽  
Prolonged Pregnancy ◽  
Stimulation Of

It has been shown that hypothyroidism in the rat produces a prolongation of pregnancy associated with a delay in the fall of circulating progesterone (P4) at term. The aim of the present work is to determine whether the delayed P4decline in hypothyroid mother rats is due to a retarded induction of P4degradation to 20αOH P4or to a stimulation of its synthesis, and to investigate the possible mechanisms that may underlie the altered luteal function. We determined by RIA the circulating profile of the hormones (TSH, PRL, LH, P4, PGF2α, and PGE2) involved in luteal regulation at the end of pregnancy and, by semiquantitative RT-PCR, the expression of factors involved in P4synthesis (CytP450scc, StAR, 3βHSD, PRLR) and metabolism (20αHSD, PGF2αR, iNOS and COX2). Our results show that the delay in P4decline and parturition is the resultant of retarded luteal regression, caused by a combination of decreases in luteolytic factors, mainly luteal PGF2α, iNOS mRNA expression and also circulating LH, and increased synthesis or action of luteotrophic factors, such as luteal and circulating PGE2 and circulating PRL. All these changes may be direct causes of the decreased 20αHSD mRNA and protein (measured by western blot analysis) expression, which in the presence of unchanged expression of the factors involved in P4synthesis results in elevated luteal and circulating P4that prolonged pregnancy and also may favor longer survival of the corpus luteum.

scholarly journals In vivo stimulation of the beta(2)-adrenergic pathway increases expression of the Gi proteins and the alpha(2)A-adrenergic receptor genes in the pregnant rat myometrium

1998 ◽  
Vol 156 (2) ◽  
pp. 379-387 ◽  
Author(s):  
JL Lecrivain ◽  
S Mhaouty-Kodja ◽  
J Cohen-Tannoudji ◽  
JP Maltier ◽  
C Legrand
Keyword(s):  
Northern Blotting ◽  
Pregnant Rats ◽  
Beta Adrenergic ◽  
Pregnant Rat ◽  
Steady State Levels ◽  
Maximal Rise ◽  
Gi Proteins ◽  
Stimulation Of

Cross-regulations between Gs and Gi mediated pathways controlling the adenylyl cyclase activity have been clearly demonstrated in vitro. To elucidate whether activation of the beta-adrenergic pathway in the pregnant myometrium might affect Gi proteins and alpha(2)-adrenergic receptors (ARs), we treated late pregnant rats from day 18 to day 21 with twice-daily administration of isoproterenol (8 mg/kg). This treatment increased myometrial cAMP levels and led after 76 h to a significant and maximal rise in the immunoreactive amount of myometrial Gi alpha 2 and Gi alpha 3 proteins (1.4- and 1.7-fold respectively) associated with a parallel increase of the steady-state levels of both Gi alpha 2 and Gi alpha 3 mRNA (1.6- and 1.9-fold respectively). Propranolol antagonized this response indicating the implication of the beta-adrenergic pathway. Nuclear run-on assays demonstrated that isoproterenol enhanced respectively by 1.3- and 1.2-fold the transcription rate of the Gi alpha 2 and Gi alpha 3 genes. Quantification of myometrial alpha(2)-ARs by [3H]rauwolscine binding revealed that the total number of receptors was also increased at 76 h by 1.7-fold when compared with controls, with no change in the affinity of the alpha(2)-ARs for the ligand. This effect was antagonized by propranolol. Quantification of both alpha(2A)- and alpha(2B)-subtypes by Northern blotting analysis demonstrated that this elevation was due to a selective increase of the alpha(2A)-subtype mRNAs. The present results indicate that in vivo stimulation of the beta-adrenergic pathway by isoproterenol increases both Gi alpha 2/Gi alpha 3 and alpha(2A)-AR expression in the pregnant rat myometrium. The possible contribution of such a mechanism in pregnancy-related changes of both entities is discussed.

Fluprostenol-induced softening of the cervix of the pregnant rat

1983 ◽  
Vol 97 (2) ◽  
pp. 283-290 ◽  
Author(s):  
L. M. Williams ◽  
M. Hollingsworth ◽  
M. Dukes ◽  
I. D. Morris
Keyword(s):  
Binding Capacity ◽  
Direct Action ◽  
Prostaglandin E ◽  
Uterine Contractility ◽  
Serum Progesterone ◽  
Pregnant Rats ◽  
Pregnant Rat ◽  
Uterine Contractions ◽  
Prostaglandin F

Fluprostenol, an analogue of prostaglandin F2α, administered s.c. to rats on day 18 of pregnancy increased cervical creep, or softness, by the following day. Doses of fluprostenol 100-fold larger were necessary to increase uterine contractions. Fluprostenol produced falls in serum progesterone concentrations, increases in 20α-dihydroprogesterone concentrations, no changes in oestradiol or relaxin concentrations and a reduction in the ovarian human chorionic gonadotrophin binding capacity in vitro. Fluprostenol was less potent in inducing cervical softness when administered per vaginam, and a dose which produced softening in pregnant rats was ineffective in ovariectomized steroid-maintained pregnant or pro-oestrous rats. The findings suggest that cervical softening by fluprostenol does not result from a simple direct action on the cervix or by increasing uterine contractions, but rather by an indirect hormonal action mediated by the ovaries. The results with the lowest dose of fluprostenol indicate that cervical softening could be produced without a sustained fall in serum progesterone concentrations. Fluprostenol is much more potent at increasing cervical softness in the pregnant rat than prostaglandin F2α or prostaglandin E2. With fluprostenol the ratio of dose to induce uterine contractility relative to that to produce cervical softness was greater than with these natural prostaglandins, indicating the greater selectivity of fluprostenol in the pregnant rat.

Distension of the uterus induces HspB1 expression in rat uterine smooth muscle

2011 ◽  
Vol 301 (5) ◽  
pp. R1418-R1426 ◽  
Author(s):  
B. G. White ◽  
D. J. MacPhee
Keyword(s):  
Protein Expression ◽  
Stress Protein ◽  
Late Pregnancy ◽  
Cytoplasmic Localization ◽  
Pregnant Rats ◽  
Pregnant Rat ◽  
Myometrial Cells ◽  
Uterine Smooth Muscle ◽  
Stimulation Of

The uterine musculature, or myometrium, demonstrates tremendous plasticity during pregnancy under the influences of the endocrine environment and mechanical stresses. Expression of the small stress protein heat shock protein B1 (HspB1) has been reported to increase dramatically during late pregnancy, a period marked by myometrial hypertrophy caused by fetal growth-induced uterine distension. Thus, using unilaterally pregnant rat models and ovariectomized nonpregnant rats with uteri containing laminaria tents to induce uterine distension, we examined the effect of uterine distension on myometrial HspB1 expression. In unilaterally pregnant rats, HspB1 mRNA and Ser15-phosphorylated HspB1 (pSer15 HspB1) protein expression were significantly elevated in distended gravid uterine horns at days 19 and 23 (labor) of gestation compared with nongravid horns. Similarly, pSer15 HspB1 protein in situ was only readily detectable in the distended horns compared with the nongravid horns at days 19 and 23; however, pSer15 HspB1 was primarily detectable in situ at day 19 in membrane-associated regions, while it had primarily a cytoplasmic localization in myometrial cells at day 23. HspB1 mRNA and pSer15 HspB1 protein expression were also markedly increased in ovariectomized nonpregnant rat myometrium distended for 24 h with laminaria tents compared with empty horns. Therefore, uterine distension plays a major role in the stimulation of myometrial HspB1 expression, and increased expression of this small stress protein could be a mechanoadaptive response to the increasing uterine distension that occurs during pregnancy.

Preparation and properties of human chorionic gonadotropin antagonist for biological studies: antifertility effects in the female rat

1986 ◽  
Vol 112 (4) ◽  
pp. 586-594 ◽  
Author(s):  
M. R. Sairam ◽  
K. Kato ◽  
A. K. Mukhopadhyay ◽  
H. G. Bohnet
Keyword(s):  
Antagonistic Activity ◽  
Female Rat ◽  
Serum Progesterone ◽  
Pregnant Rats ◽  
Pregnant Rat ◽  
Trifluoromethane Sulfonic Acid ◽  
Ovarian Granulosa Cell ◽  
Biological Studies ◽  
Stable Product ◽  
High Level

Abstract. We compared the effects of treatment of clinical grade hCG powders with anhydrous HF (hydrogen fluoride) or TFMS (trifluoromethane sulfonic acid). HF treatment yielded stable product (DG-hCG), which had desirable antagonistic activity in mouse Leydig cells. Binding of HF-hCG to ovarian granulosa cell FSH receptors was < 5% as compared to purified ovine FSH. As LH/hCG receptor specificity was not significantly compromised crude hCG could be directly used in obtaining large amounts of the antagonist. The effects of antagonist (DG-hCG) and agonists crude hCG and purified hCG were evaluated in pregnant rats. When administered between days 1 to 5 of pregnancy, crude DG-hCG inhibited serum progesterone and oestradiol levels and implantation. The effect was dose-dependent. However, both crude hCG and purified hCG elevated progesterone level and partially inhibited implantation (up to about 40%). In the post-implantation period (days 8–11) crude DG-hCG treatment induced abortion due to a decrease in circulating progesterone and oestradiol levels. The agonists, crude hCG and purified hCG, on the other hand, elevated both steroid levels in serum and induced partial termination of pregnancy (up to 50%). During the second half of pregnancy, when luteotropic support of LH becomes unnecessary in the rat, crude DG-hCG (antagonist) had no effect on parturition. However, crude or purified hCG caused delay in parturition by sustaining high level of progesterone in circulation. Our data demonstrate that the antifertility effects of crude DG-hCG are more potent and consistent than the administration of either crude or purified hCG in the pregnant rat.

EFFECTS OF AN ANTISERUM TO LUTEINIZING HORMONE AND STEROID REPLACEMENT THERAPY ON MAINTENANCE OF PREGNANCY IN THE RAT: SERUM AND LUTEAL LEVELS OF PROGESTERONE, TESTOSTERONE AND OESTRADIOL

1981 ◽  
Vol 90 (1) ◽  
pp. 9-18 ◽  
Author(s):  
P. F. TERRANOVA ◽  
G. S. GREENWALD
Keyword(s):  
Testosterone Propionate ◽  
Normal Values ◽  
Single Injection ◽  
Vaginal Smear ◽  
Corpora Lutea ◽  
Serum Progesterone ◽  
Rat Serum ◽  
Pregnant Rats ◽  
Pregnant Rat ◽  
Daily Dose

Pregnant rats were injected s.c. with antiserum to LH (anti-LH) on days 8 or 10 of pregnancy (day 1 = day of sperm-positive vaginal smear) and subsequently given various steroids s.c. to prevent luteolysis and/or abortion. A single injection of 4 mg progesterone on day 8 prevented abortion and luteolysis as shown on day 12 by the presence of fetal swellings and levels of progesterone in serum (88 ±6 (s.e.m.) ng/ml) and corpora lutea (26±3 ng/mg) comparable to control values. After 0·5 ml anti-LH on day 10, a daily dose of 4 mg progesterone prevented abortion in five out of eight animals but by day 13 luteal progesterone was 3·0 ± 0·7 compared with 24±3 ng/mg in controls. After anti-LH on day 8 or 10, daily injections of 1 or 4 mg testosterone propionate or 10 μg, 100 μg or 1 mg oestradiol failed to prevent abortion or to raise luteal concentrations of progesterone to normal values. However, 4 mg testosterone propionate on day 8 or 100 or 500 μg oestradiol on day 10 maintained serum progesterone levels at approximately half those of control values. Treatment with 4 mg testosterone propionate on days 8–11 led to significant increases in serum and luteal levels of testosterone and oestradiol on day 12; on day 10 exogenous oestradiol (100 or 500 μg) increased serum and luteal levels of oestradiol by day 13. These results, especially treatments begun on day 8, are difficult to reconcile with the current concept that the luteotrophic action of LH in the pregnant rat is exerted by increasing luteal androgens that are aromatized to oestrogens which then act as the direct luteotrophic stimulus.

Sign in / Sign up

Export Citation Format

Share Document